Liminatus Pharma, Inc. Class A Common Stock
Liminatus Pharma, Inc. Class A Common Stock (LIMN) Revenue
Annual & quarterly revenue history · segment & region breakdown
LIMN · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsLiminatus Pharma, Inc. Class A Common Stock trailing twelve-month (TTM) revenue is $0.00B, an increase of 0.00% year-over-year from — in FY.
Revenue trend
– · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Liminatus Pharma, Inc. Class A Common Stock receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Liminatus Pharma, Inc. Class A Common Stock reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Liminatus Pharma, Inc. Class A Common Stock's 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
LIMN revenue · 4 questionsLIMN's trailing twelve-month (TTM) revenue is $0.00B. That is an increase of 0.00% year-over-year from — in FY.
▸ Source: FMP · Liminatus Pharma, Inc. Class A Common Stock SEC filings · GAAP · Liminatus Pharma, Inc. Class A Common Stock SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026